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Abstract
Background: Although previous studies have identified high levels of drug-related harm in Thailand, little is known 
about illicit drug overdose experiences among Thai drug users. We sought to investigate non-fatal overdose 
experiences and responses to overdose among a community-recruited sample of injection drug users (IDU) in 
Bangkok, Thailand.
Methods: Data for these analyses came from IDU participating in the Mit Sampan Community Research Project. The 
primary outcome of interest was a self-reported history of non-fatal overdose. We calculated the prevalence of past 
overdose and estimated its relationship with individual, drug-using, social, and structural factors using multivariate 
logistic regression. We also assessed the prevalence of ever witnessing an overdose and patterns of response to 
overdose.
Results: These analyses included 252 individuals; their median age was 36.5 years (IQR: 29.0 - 44.0) and 66 (26.2%) were 
female. A history of non-fatal overdose was reported by 75 (29.8%) participants. In a multivariate model, reporting a 
history of overdose was independently associated with a history of incarceration (Adjusted Odds Ratio [AOR] = 3.83, 
95% Confidence Interval [CI]: 1.52 - 9.65, p = 0.004) and reporting use of drugs in combination (AOR = 2.48, 95% CI: 1.16 
- 5.33, p = 0.019). A majority (67.9%) reported a history of witnessing an overdose; most reported responding to the 
most recent overdose using first aid (79.5%).
Conclusions: Experiencing and witnessing an overdose were common in this sample of Thai IDU. These findings 
support the need for increased provision of evidence-based responses to overdose including peer-based overdose 
interventions.
Background
Accidental illicit drug-related overdose is a leading cause
of preventable morbidity and mortality. In many settings,
fatal overdose is the primary contributor to highly ele-
vated mortality rates among injection drug users (IDU)
[1,2]. According to several studies of community-
recruited IDU, non-fatal overdose is common and associ-
ated with factors including having a prior history of over-
dose, recent incarceration and higher-intensity forms of
drug use, such as poly-drug use [3-6]. Several interven-
tions to lower the incidence or reduce the damaging
sequelae of overdose events have been implemented,
including treatment for drug use [7], drug substitution
therapy [8], supervised injection facilities [9] and peer-
driven responses, such as naloxone distribution [10].
Despite reports of injection drug use from all major
regions of the world [11,12], the phenomenon of acciden-
tal drug overdose has not been well described outside of
Western settings. In northern Vietnam, over 80% of out-
of-treatment male opiate injectors reported a history of
overdose in a cross-sectional survey [13]. Overdose in the
previous 12 months was common among 731 IDU in
Sichuan province, China, and associated with daily her-
oin use and an injection career of at least seven years in
duration [14].
In Thailand, some aspects of drug-related harm,
including high levels of incarceration [15], persecution by
police [16] and infection with HIV [17,18] hepatitis C [19]
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and other pathogens [20] have been identified among the
estimated 20,000 - 160,000 IDU in the country [11,12].
However, we are unaware of any study that analyses the
phenomenon of overdose among Thai drug users. Thus,
we sought to estimate the prevalence and correlates of
non-fatal overdose, as well as investigate patterns of
response to overdose in a community-recruited sample of
active IDU in Bangkok, Thailand.
Methods
Data for these analyses was obtained from the Mit Sam-
pan Community Research Project (MSCRP), a collabora-
tive research effort involving the Mit Sampan Harm
Reduction Center (Bangkok, Thailand), the Thai AIDS
Treatment Action Group (Bangkok, Thailand), Chula-
longkorn University (Bangkok, Thailand) and the British
Columbia Centre for Excellence in HIV/AIDS (Vancou-
ver, Canada). In 2008, the research partners designed and
undertook a cross-sectional epidemiological study of IDU
recruited through peer-based outreach and word-of-
mouth. Invited participants were asked to attend the Mit
Sampan Harm Reduction Center to be included in the
study. All participants provided informed consent and
completed an interviewer-administered questionnaire.
The survey instrument elicited demographic data, infor-
mation about past and current drug use, HIV risk behav-
iour, overdose experiences, interactions with the criminal
justice system including police forces and incarceration,
and experience with health care. Upon completion of the
questionnaire participants were provided a stipend of 250
Thai baht. The study was approved by the research ethics
boards at the University of British Columbia and Chula-
longkorn University.
For these analyses, the primary endpoint of interest was
reporting a history of non-fatal overdose by answering
"Yes" to the question: "Have you ever overdosed by acci-
dent (i.e., a period of loss of consciousness or breathing?)"
In follow-up questions, individuals reporting a history of
non-fatal overdose were also asked the type of drug or
drugs they were using at the time of their last overdose, if
they were helped, and by who, during their last overdose.
As a first step, we investigated the characteristics of
individuals with a history of overdose. Explanatory vari-
ables included: Age; gender (male vs. female); education
level (<prathom suksa [elementary-level] vs. ≥ prathom
suksa); reporting any income from illegal sources (yes vs.
no); participation in the sex trade (yes vs. no); history of
heroin injection (yes vs. no); history of Midazolam (a
benzodiazepine) injection (yes vs. no); history of yaba
(methamphetamine and caffeine) injection (yes vs. no);
history of ice (methamphetamine) injection (yes vs. no);
history of using drugs in combination (yes vs. no); history
of methadone injection (yes vs. no); ever using an unster-
ile syringe (yes vs. no); ever lending syringes (yes vs. no);
ever incarcerated (yes vs. no); ever on methadone mainte-
nance therapy (MMT) (yes vs. no); and ever in forced
drug treatment (yes vs. no). Pearson's X2-test and Fisher's
exact test were used to determine bivariate relationships.
Next, we used an a priori-defined statistical protocol
based on examination of the Akaike Information Crite-
rion (AIC) and p-values to construct an explanatory mul-
tivariate logistic regression model. First, we constructed a
full model including all variables analysed in bivariate
analyses. After noting the AIC of the model, we removed
the variable with the largest p-value and built a reduced
model. We continued this iterative process until no vari-
ables remained for inclusion. We selected the multivari-
ate model with the lowest AIC score.
In a secondary analysis, all participants were asked if
they had ever witnessed an overdose. Those with a his-
tory of witnessing overdose were asked about their
response to the most recently witnessed overdose. Finally,
all participants were asked if they believed they had
enough information to prevent and manage overdose and
what steps they believe should be taken to effectively
manage overdose.
Results
Two-hundred fifty-two individuals were recruited and
included in these analyses, of whom 66 (26.1%) were
women. The median age at time of interview was 36.5
years (IQR: 29.0 - 44.0 years.) In total, 75 participants
(29.8%) reported a history of non-fatal overdose. When
asked about the type and routes of administration of all
drugs consumed prior to their last overdose, almost all
(70, 93.3%) reported injection heroin, followed by injec-
tion Midazolam (24, 32.0%), non-injection heroin (11,
14.7%) and non-injection midazolam (4, 5.3%). No other
response (including injection and non-injection yaba,
non-injection ecstasy, injection and non-injection metha-
done, injection and non-injection benzodiazepine and
injection and non-injection alcohol) exceeded three
(4.0%) reports.
Of the 75 participants with a history of overdose, 59
(78.7%) reported being helped by another individual dur-
ing their last overdose. Most reported being assisted by a
friend (46, 78.0%), relative (11, 18.6%) or sex partner (3,
5.1%). Of all individuals reporting an overdose, only 28
(33.5%) reported being seen by a healthcare professional.
Results of the univariate analyses of factors associated
with reporting a history of non-fatal overdose are pre-
sented in Table 1. As shown, the outcome was associated
at the p < 0.05 level with: reporting a history of incarcera-
tion (Odds Ratio [OR] = 4.40, 95% Confidence Interval
[CI]: 1.80 - 10.79); a history of using drugs in combination
(OR = 3.05, 95% CI: 1.53 - 6.07); and a history of injecting
Midazolam (OR = 2.20, 95% CI: 1.67 - 4.12). A history of
injecting heroin was significantly associated with report-Milloy et al. Harm Reduction Journal 2010, 7:9
http://www.harmreductionjournal.com/content/7/1/9
Page 3 of 7
Table 1: Univariate analyses of factors associated with reporting a history of non-fatal overdose among IDU in MSHRC 
cohort (n = 252 individuals).
Characteristic History of overdose n (%) OR1 95% CI2 p-val
No: 177 (70.2) Yes: 75 (29.8)
AGE
Median (IQR) 37.0 (29.5 - 44.5) 35.0 (28.0 - 42.0) 0.99 0.97 - 1.03 0.843
GENDER
Male 130 (73.4) 56 (74.7)
Female 47 (26.6) 19 (25.3) 0.93 0.51 - 1.74 0.877
EDUCATION
≥ Secondary 110 (62.1) 50 (66.7) 1.00
< Secondary 37 (37.9) 25 (33.4) 0.82 0.47 - 1.45 0.568
SEX TRADE
No 167 (94.4) 71 (94.7) 1.00
Yes 10 (5.6) 4 (5.3) 0.94 0.29 - 3.10 0.841
EVER INJECT HEROIN
No 18 (10.1) 0 (0.0)
Yes 159 (89.9) 75 (100.0 0.002
EVER INJECT YABA
No 66 (37.3) 25 (33.3) 1.00
Yes 111 (62.7) 50 (66.7) 1.19 0.67 - 2.10 0.570
EVER INJECT MIDAZOLAM
No 66 (37.3) 16 (21.3) 1.00
Yes 111 (62.7) 59 (78.7) 2.20 1.67 - 4.12 0.018
EVER INJECT BENZODIAZEPINES
No 174 (98.3) 73 (97.3) 1.00Milloy et al. Harm Reduction Journal 2010, 7:9
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ing ever experiencing a non-fatal overdose (p = 0.002);
however, as all individuals with a history of overdose also
reported a history of heroin injection, an Odds Ratio
could not be calculated and that explanatory factor was
removed from further consideration. The final multivari-
ate model, presented in Table 2, included two factors
independently associated with the outcome: Ever using
drugs in combination (Adjusted Odds Ratio [AOR] =
2.48, 95% CI: 1.16 - 5.33) and reporting a history of incar-
ceration (AOR = 3.83, 95% CI: 1.52 - 9.65).
Experience witnessing an overdose was reported by 171
(67.9%) participants. When asked their response to the
last overdose witnessed, most (136, 79.5%) reported per-
forming first aid; 78 (45.6%) took the overdose sufferer to
a hospital; 4 (2.3%) took them to the Mit Sampan Harm
Reduction Centre; 1 (0.6%) contacted the police. Twelve
individuals (7.0%) reported they did nothing in response.
Approximately half of the participants reported they
believed they had enough information to prevent (139,
55.2%) and manage (128, 50.8%) an overdose. When
asked how to manage an overdose, responses were: per-
form first aid (115, 45.6%); inject salt water (109, 43.2%);
perform CPR (90, 35.7%); slap (105, 41.7%); administer
naloxone (16, 6.3%); or take to a hospital (74, 29.4%).
Discussion
In these analyses, we found a history of non-fatal over-
dose was common among Thai IDU, with more than one-
quarter of the sample (29.8%) reporting a previous over-
dose event. The predominant drug implicated in over-
Yes 3 (1.7) 2 (2.7) 1.59 0.26 - 9.71 0.636
EVER INJECT METHADONE
No 150 (84.7) 63 (84.0) 1.00
Yes 27 (15.3) 12 (16.0) 1.06 0.50 - 2.22 0.851
EVER USE DRUGS IN COMBINATION
No 65 (36.7) 12 (16.0) 1.00
Yes 112 (63.3) 63 (84.0) 3.05 1.53 - 6.07 < 0.001
EVER INCARCERATED
No 49 (27.7) 6 (8.0) 1.00
Yes 128 (72.3) 69 (92.0) 4.40 1.80 - 10.79 < 0.001
EVER ON MMT
No 102 (57.7) 39 (52.0) 1.00
Yes 75 (42.3) 36 (48.0) 1.26 0.73 - 2.16 0.488
EVER IN FORCED DRUG TREATMENT
No 127 (71.8) 45 (60.0) 1.00
Yes 50 (28.2) 30 (40.0) 1.69 0.96 - 2.82 0.076
1. Odds Ratio; 2. 95% Confidence Interval
Table 1: Univariate analyses of factors associated with reporting a history of non-fatal overdose among IDU in MSHRC 
cohort (n = 252 individuals). (Continued)Milloy et al. Harm Reduction Journal 2010, 7:9
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dose events was heroin, with the majority of individuals
reporting injecting heroin before their last overdose and
every individual with a history of overdose also reporting
a history of heroin use. In a multivariate model, a history
of overdose was linked to poly-drug use and incarcera-
tion. Most of the participants also reported experience
witnessing an overdose (67.9%) and the most common
responses included performing first aid and taking the
victim to a hospital. When asked how to manage an over-
dose, the most common responses included performing
first aid or artificial respiration and injecting salt water.
The level of non-fatal overdose observed in this sample
is on the lower end of the range of estimates calculated in
similar studies of community-based IDU in Baltimore,
Maryland (24.7%) [21]; London, England (37.8%) [22] and
San Francisco, California (47.9%) [23]. We are unable to
determine if this comparatively lower level is the result of
a lower incidence of overdose among Thai IDU or a
g r e a t e r  r i s k  o f  d e a t h  a t  e a c h  o v e r d o s e  e v e n t .  S e v e r a l
points of evidence support a contribution from the latter
effect, including the high prevalence of witnessing over-
doses; the pervasive level of misperceptions concerning
how to manage an overdose; the high prevalence of over-
dose as the reported cause of death among Thai IDU in
two HIV vaccine preparatory studies [24,25]; and the
ongoing violent crackdown by Thai police against drug
users, a phenomenon linked to a greater risk of overdose
mortality in other settings [26-28].
Our findings identify the need for enhanced education
for Thai IDU to prevent and manage overdoses. Specifi-
cally, approximately half of respondents indicated they
did not have the information required to prevent and
manage overdoses. This lack of knowledge was reflected
in the substantial proportion of participants reporting
inappropriate responses, including injecting the sufferer
with salt water. Given that witnessing an overdose was
common in this setting and fatal overdoses typically take
hours to develop [29,30], the need to improve peer
responses is clear. Inappropriate or suboptimal responses
by IDU to overdose are not uncommon and have been
reported from a number of settings [26,29,31]. However,
overdose management education has been shown to be
effective at training IDU to respond appropriately to
overdose [26,32].
These findings also support the distribution of nalox-
one to drug users. Naloxone, an opiate antagonist, is the
standard treatment used by healthcare professionals in
resuscitation efforts following opioid overdose. Programs
to train IDU in overdose response alongside distribution
of naloxone would likely benefit Thai IDU, given that opi-
ates were the most common class of drugs reported by
this sample prior to their last overdose. Additionally,
given pervasive anti-drug user stigma [33,34] and the
ongoing violent campaign by police [35], many IDU may
be unwilling to seek professional health care in the event
of an overdose. Evaluations of analagous interventions in
Chicago [36], New York City [10] and San Francisco [37]
have observed positive impacts, including hundreds of
successful peer opioid overdose resuscitations. Currently,
n a l o x o n e  i s  o n l y  a v a i l a b l e  t o  I D U  i n  T h a i l a n d  a t  t h e
MSHRC.
In the multivariate model, a history of incarceration
was independently associated with ever overdosing. This
is in line with previous analyses that have identified a
high risk of overdose, including fatal overdose, associated
with incarceration, especially in the first weeks following
release from detention [38,39]. In the Thai context, previ-
ous studies have described the links between exposure to
correctional environments and an elevated risk of HIV
infection among IDU [40,41]. Our findings add evidence
supporting the need for an expansion of harm reduction
opportunities in Thai correctional settings, such as sub-
stitution therapies, shown effective at reducing HIV risk
Table 2: Multivariate logistic regression analysis of factors associated with reporting a history of non-fatal overdose in 
MSHRC cohort (n = 252 individuals).
Characteristic AOR1 95% CI2 p-value
Ever injected Midazolam (Yes 
vs. no)
1.38 0.68 - 2.81 0.379
Ever used in combination (Yes 
vs. no)
2.48 1.16 - 5.33 0.020
Ever incarcerated (Yes vs. no) 3.83 1.52 - 9.65 0.004
Ever in forced treatment (Yes 
vs. no)
1.25 0.69 - 2.28 0.457
1. Adjusted Odds Ratio; 2. 95% Confidence IntervalMilloy et al. Harm Reduction Journal 2010, 7:9
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behaviours [42] and improving outcomes post-release
[43].
While the implementation of peer-based interventions
might lower the incidence and severity of overdose events
among Thai IDU, our findings also have implications for
other social- and structural-level policies. In particular,
our findings are another example of how the reliance on
enforcement-based strategies to respond to illicit drug
use can produce further drug-related harms [44,45]. Just
as some observers have identified deaths resulting from
the Thai government's crackdown on drug users [35], our
findings describe how criminal justice interventions can
increase the risks associated with overdose events. We
echo other authors who have credited the country's suc-
cessful efforts to reduce the incidence of sexually-trans-
mitted HIV infections to the government's adoption of
evidence-based policies [41,46] and urge a similar prag-
matic initiative to replace dominant enforcement- and
suppression-based policies with harm reduction pro-
grammes.
Our study has limitations. First, cross-sectional analy-
ses are unable to determine the temporal relationship
between outcome and exposure. Second, although our
measures are based on self-reports from IDU, we do not
believe participants would have been more or less likely
to report a history of overdose based on the covariates we
examined. Finally, our sample of IDU was not recruited at
random and thus may not necessarily generalize to other
samples of IDU in Thailand or other settings.
Conclusions
We observed that non-fatal overdose events were com-
mon in this sample of Thai IDU. In a multivariate analy-
sis, reporting a history of non-fatal overdose was
independently associated with ever being incarcerated
and ever using drugs in combination. A majority of par-
ticipants reported witnessing overdoses as well as need-
ing more information to respond appropriately. Our
findings support the need to expand appropriate harm
reduction strategies for drug users in Thailand, such as
peer-based overdose management including naloxone
distribution, and further highlight the need to balance the
current emphasis on enforcement-based responses to
illicit drug use with health-focused interventions.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TK, EW, PS and KK conceived and designed the study; KK, PS, NF and KH imple-
mented the study design, including data acquisition; M-JM performed the sta-
tistical analysis, wrote the manuscript and coordinated all revisions; all authors
revised the manuscript and read and approved the final draft.
Acknowledgements
We would like to thank the staff and volunteers at the Mitsampan Harm Reduc-
tion Center for their support. We also thank Dr. Niyada Kiatying-Angsulee of the 
Social Pharmacy Research Unit (SPR), Faculty of Pharmaceutical Sciences, Chu-
lalongkorn University, for her assistance with developing this project. We also 
thank Deborah Graham and Calvin Lai for their assistance with data manage-
ment; Prempreeda Pramoj Na Ayutthaya and Donlachai Hawangchu for their 
assistance with data collection. This work was funded by the Canadian Insti-
tutes of Health Research (Grant RAA-79918).
Author Details
1School of Population and Public Health, University of British Columbia, 5804 
Fairview Avenue, Vancouver, British Columbia, V6T 1C3, Canada, 2British 
Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 667-1081 
Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada, 3Thai AIDS 
Treatment Action Group, 18/89 Vipawadee Road, soi 40, Chatuchak, Bangkok, 
Thailand and 4Department of Medicine, University of British Columbia, Room 
10203, 2775 Laurel Street, Vancouver, British Columbia, V5Z 1M9, Canada
References
1. Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, 
Brugal T, Vicente J, Group CE: Drug-related mortality and its impact on 
adult mortality in eight European countries.  European journal of public 
health 2006, 16:198-202.
2. Centers for Disease Control: Unintentional poisoning deaths--United 
States, 1999-2004.  MMWR Morb Mortal Wkly Rep 2007, 56:93-96.
3. Darke S, Hall W: Heroin overdose: research and evidence-based 
intervention.  J Urban Health 2003, 80:189-200.
4. Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson M: Patterns of 
nonfatal heroin overdose over a 3-year period: findings from the 
Australian treatment outcome study.  Journal of urban health: bulletin of 
the New York Academy of Medicine 2007, 84:283-291.
5. Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, Wood E: 
Predictors of non-fatal overdose among a cohort of polysubstance-
using injection drug users.  Drug Alcohol Depend 2007, 87:39-45.
6. Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, Moss AR: Heroin 
overdose among young injection drug users in San Francisco.  Drug 
Alcohol Depend 2005, 80:297-302.
7. Darke S, Williamson A, Ross J, Teesson M: Non-fatal heroin overdose, 
treatment exposure and client characteristics: findings from the 
Australian treatment outcome study (ATOS).  Drug Alcohol Rev 2005, 
24:425-432.
8. van Ameijden EJ, Langendam MW, Coutinho RA: Dose-effect 
relationship between overdose mortality and prescribed methadone 
dosage in low-threshold maintenance programs.  Addict Behav 1999, 
24:559-563.
9. Milloy MJ, Kerr T, Tyndall M, Montaner J, Wood E: Estimated drug 
overdose deaths averted by North America's first medically-supervised 
safer injection facility.  PLoS ONE 2008, 3:e3351.
10. Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, Galea S: 
Evaluation of a naloxone distribution and administration program in 
New York City.  Subst Use Misuse 2008, 43:858-870.
11. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M: 
Estimates of injecting drug users at the national and local level in 
developing and transitional countries, and gender and age 
distribution.  Sexually transmitted infections 2006, 82(Suppl 3):iii10-17.
12. Aceijas C, Stimson GV, Hickman M, Rhodes T, United Nations Reference 
Group on HIV/AIDS Prevention and Care among IDU in Developing and 
Transitional Countries: Global overview of injecting drug use and HIV 
infection among injecting drug users.  AIDS 2004, 18:2295-2303.
13. Bergenstrom A, Quan VM, Van Nam L, McClausland K, Thuoc NP, 
Celentano D, Go V: A cross-sectional study on prevalence of non-fatal 
drug overdose and associated risk characteristics among out-of-
treatment injecting drug users in North Vietnam.  Subst Use Misuse 
2008, 43:73-84.
14. Yin L, Qin G, Ruan Y, Qian H, Hao C, Xie L, Chen K, Zhang Y, Xia Y, Wu J, et 
al.: Nonfatal overdose among heroin users in southwestern China.  The 
American journal of drug and alcohol abuse 2007, 33:505-516.
15. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N, 
Vongchuk T, Tovanabutra S, Sripaipan T, Celentano DD: Drug use, 
Received: 26 October 2009 Accepted: 13 May 2010 
Published: 13 May 2010
This article is available from: http://www.harmreductionjournal.com/content/7/1/9 © 2010 Milloy et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Harm Reduction Journal 2010, 7:9Milloy et al. Harm Reduction Journal 2010, 7:9
http://www.harmreductionjournal.com/content/7/1/9
Page 7 of 7
increasing incarceration rates, and prison-associated HIV risks in 
Thailand.  AIDS and behavior 2003, 7:153-161.
16. Kerr T, Kaplan K, Suwannawong P, Wood E: Health and human rights in 
the midst of a drug war: the Thai Drug Users' Network.  In Public health 
and human rights: Evidence-based approaches Edited by: Beyrer C, Pizer H. 
Baltimore, Maryland, United States: Johns Hopkins; 2007. 
17. Celentano DD, Hodge MJ, Razak MH, Beyrer C, Kawichai S, Cegielski JP, 
Nelson KE, Jittiwutikarn J: HIV-1 incidence among opiate users in 
northern Thailand.  Am J Epidemiol 1999, 149:558-564.
18. Latkin CA, Donnell D, Metzger D, Sherman S, Aramrattna A, Davis-Vogel A, 
Quan VM, Gandham S, Vongchak T, Perdue T, Celentano DD: The efficacy 
of a network intervention to reduce HIV risk behaviors among drug 
users and risk partners in Chiang Mai, Thailand and Philadelphia, USA.  
Soc Sci Med 2008:740-748.
19. Jittiwutikarn J, Thongsawat S, Suriyanon V, Maneekarn N, Celentano D, 
Razak MH, Srirak N, Vongchak T, Kawichai S, Thomas D, et al.: Hepatitis C 
infection among drug users in northern Thailand.  Am J Trop Med Hyg 
2006, 74:1111-1116.
20. Celentano DD, Sirirojn B, Sutcliffe CG, Quan VM, Thomson N, Keawvichit R, 
Wongworapat K, Latkin C, Taechareonkul S, Sherman SG, Aramrattana A: 
Sexually transmitted infections and sexual and substance use 
correlates among young adults in Chiang Mai, Thailand.  Sex Transm Dis 
2008, 35:400-405.
21. Latkin CA, Hua W, Tobin K: Social network correlates of self-reported 
non-fatal overdose.  Drug Alcohol Depend 2004, 73:61-67.
22. Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C, Welch S, Gossop M: 
Preventing opiate overdose fatalities with take-home naloxone: pre-
launch study of possible impact and acceptability.  Addiction 1999, 
94:199-204.
23. Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, Edlin BR: 
Predictors and prevention of nonfatal overdose among street-
recruited injection heroin users in the San Francisco Bay Area, 1998-
1999.  Am J Public Health 2001, 91:1842-1846.
24. Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des Jarlais DC, 
Sujarita S, Srisuwanvilai LO, Young NL, Wasi C, et al.: Continued high HIV-1 
incidence in a vaccine trial preparatory cohort of injection drug users 
in Bangkok, Thailand.  AIDS 2001, 15:397-405.
25. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven 
F, Hu D, Tappero JW, Choopanya K: Randomized, double-blind, placebo-
controlled efficacy trial of a bivalent recombinant glycoprotein 120 
HIV-1 vaccine among injection drug users in Bangkok, Thailand.  J 
Infect Dis 2006, 194:1661-1671.
26. Pollini RA, McCall L, Mehta SH, Celentano DD, Vlahov D, Strathdee SA: 
Response to overdose among injection drug users.  Am J Prev Med 2006, 
31:261-264.
27. Tracy M, Piper TM, Ompad D, Bucciarelli A, Coffin PO, Vlahov D, Galea S: 
Circumstances of witnessed drug overdose in New York City: 
implications for intervention.  Drug Alcohol Depend 2005, 79:181-190.
28. Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J, 
Ciccarone D, Edlin BR: Attitudes about prescribing take-home naloxone 
to injection drug users for the management of heroin overdose: a 
survey of street-recruited injectors in the San Francisco Bay Area.  J 
Urban Health 2003, 80:291-301.
29. Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR: Fatal 
heroin-related overdose in San Francisco, 1997-2000: a case for 
targeted intervention.  J Urban Health 2003, 80:261-273.
30. Zador D, Sunjic S, Darke S: Heroin-related deaths in New South Wales, 
1992: toxicological findings and circumstances.  Med J Aust 1996, 
164:204-207.
31. Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR: Witnessing heroin-
related overdoses: the experiences of young injectors in San Francisco.  
Addiction 2002, 97:1511-1516.
32. Green TC, Heimer R, Grau LE: Distinguishing signs of opioid overdose 
and indication for naloxone: an evaluation of six overdose training and 
naloxone distribution programs in the United States.  Addiction 2008, 
103:979-989.
33. Chan KY, Stoove MA, Sringernyuang L, Reidpath DD: Stigmatization of 
AIDS patients: disentangling Thai nursing students' attitudes towards 
HIV/AIDS, drug use, and commercial sex.  AIDS Behav 2008, 12:146-157.
34. Simmonds L, Coomber R: Injecting drug users: A stigmatised and 
stigmatising population.  Int J Drug Policy 2007:121-130.
35. Human Rights Watch: Not enough graves: The war on drugs, HIV/AIDS, 
and violations of human rights.  New York City, New York, United States: 
Human Rights Watch; 2004. 
36. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S: Prescribing 
naloxone to actively injecting heroin users: a program to reduce heroin 
overdose deaths.  J Addict Dis 2006, 25:89-96.
37. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, Downing M, 
Edlin BR: Naloxone distribution and cardiopulmonary resuscitation 
training for injection drug users to prevent heroin overdose death: a 
pilot intervention study.  J Urban Health 2005, 82:303-311.
38. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, 
Koepsell TD: Release from prison--a high risk of death for former 
inmates.  N Engl J Med 2007, 356:157-165.
39. Farrell M, Marsden J: Acute risk of drug-related death among newly 
released prisoners in England and Wales.  Addiction 2008, 103:251-255.
40. Buavirat A, Page-Shafer K, van Griensven GJ, Mandel JS, Evans J, 
Chuaratanaphong J, Chiamwongpat S, Sacks R, Moss A: Risk of prevalent 
HIV infection associated with incarceration among injecting drug users 
in Bangkok, Thailand: case-control study.  BMJ 2003, 326:308.
41. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N, 
Vongchuk T, Tovanabutra S, Sripaipan T, Celentano DD: Drug use, 
increasing incarceration rates, and prison-associated HIV risks in 
Thailand.  AIDS Behav 2003, 7:153-161.
42. Sorensen JL, Copeland AL: Drug abuse treatment as an HIV prevention 
strategy: a review.  Drug Alcohol Depend 2000, 59:17-31.
43. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE: A randomized clinical 
trial of methadone maintenance for prisoners: findings at 6 months 
post-release.  Addiction 2008, 103:1333-1342.
44. Kerr T, Small W, Wood E: The public health and social impacts of drug 
market enforcement: A review of the evidence.  Int J Drug Policy 2005, 
16:210-220.
45. Maher L, Dixon D: Policing and public health: Law enforcement and 
harm minimization in a street-level drug market.  British Journal of 
Criminology 1999, 39:488-512.
46. Celentano DD: HIV prevention among drug users: an international 
perspective from Thailand.  J Urban Health 2003, 80:iii97-105.
doi: 10.1186/1477-7517-7-9
Cite this article as: Milloy et al., Overdose experiences among injection drug 
users in Bangkok, Thailand Harm Reduction Journal 2010, 7:9